CEFTRIAXONE SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Ceftriaxone Sodium patents expire, and when can generic versions of Ceftriaxone Sodium launch?
Ceftriaxone Sodium is a drug marketed by Anda Repository and Hikma and is included in two NDAs.
The generic ingredient in CEFTRIAXONE SODIUM is ceftriaxone sodium. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ceftriaxone sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ceftriaxone Sodium
A generic version of CEFTRIAXONE SODIUM was approved as ceftriaxone sodium by ANDA REPOSITORY on January 20th, 2017.
Summary for CEFTRIAXONE SODIUM
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 76 |
Clinical Trials: | 22 |
Patent Applications: | 6,545 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CEFTRIAXONE SODIUM at DailyMed |
Recent Clinical Trials for CEFTRIAXONE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ahmad Zia | Phase 3 |
Nadeem Iqbal | Phase 3 |
Muhammad Junaid Tahir | Phase 3 |
Pharmacology for CEFTRIAXONE SODIUM
Drug Class | Cephalosporin Antibacterial |
Medical Subject Heading (MeSH) Categories for CEFTRIAXONE SODIUM
Anatomical Therapeutic Chemical (ATC) Classes for CEFTRIAXONE SODIUM
US Patents and Regulatory Information for CEFTRIAXONE SODIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anda Repository | CEFTRIAXONE SODIUM | ceftriaxone sodium | INJECTABLE;INJECTION | 091117-001 | Jan 20, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Hikma | CEFTRIAXONE SODIUM | ceftriaxone sodium | INJECTABLE;INJECTION | 090701-001 | Oct 4, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |